CorriXR Therapeutics
PrivateLast Round
Series A
Aug 19, 2025
Total Funding Raised
$9M
Momentum Score
25 /100
Company Overview
CorriXR Therapeutics is a biotechnology company that is developing a gene editing platform to develop new genetic medicines directed against drug-resistant solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CorriXR Therapeutics Comps
Public and private peers based on sector, stage, and business model.
CorriXR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 19, 2025 | ||||
| Seed | Jan 22, 2024 | ||||
| Seed | Oct 11, 2022 |
Key People
Founding team and executive leadership
CorriXR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Delaware Division of Small Business | Series A |
| Cortado Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2026
Developing an inhaler device for cancer treatment delivery.
- Dec 2, 2025
Partnered with InhaTarget Therapeutics and Merxin Ltd.
CorriXR Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CorriXR Therapeutics's valuation, stock price, and market status.
